FFC#22/2015

A systematic investigation of miglustat-derivative iminosugar clusters as possible anti-inflammatory agents for Cystic Fibrosis lung disease

FFC#22/2015

A systematic investigation of miglustat-derivative iminosugar clusters as possible anti-inflammatory agents for Cystic Fibrosis lung disease

PRINCIPAL INVESTIGATOR

Maria Cristina Dechecchi (Laboratorio di Patologia Molecolare, Dipartimento di Patologia e Diagnostica – Università di Verona)

Partner

Massimo Aureli (Dip. di Biotecnologia Medica e Medicina Traslazionale – Università di Milano)

RESEARCHERS

18

CATEGORY

AREA 4 Lung inflammation

DURATION

2 years

GOAL

€ 80.000 €

RESULTS

This study was aimed to identify more efficient miglustat analogues with anti-inflammatory activity and selective GBA2 action.The focus was given on multivalent iminosugars, on L enantiomers, and on racemic mixtures composed by D and L enantiomers. The effects of these compounds on inflammatory response and cell toxicity in CF bronchial cells and murine models of lung infection were studied. Nanomolar concentrations of monovalent and multivalent DNJ iminosugars and racemic mixtures of N-alkylated iminosugars produced an anti-inflammatory effect in CF bronchial cells. Combination of low doses of miglustat and its L enantiomer was more potent than miglustat alone and reduced the inflammatory response to P.aeruginosa also in CF primary cells.No toxicity was observed both in vitro and in vivo. Combination of low doses of miglustat and its L enantiomer administered to C57Bl/6NCr mice 24 hours before bacterial inoculum improved the capability to resist P. aeruginosa infection. These results confirm that DNJ iminosugars are effective in reducing the inflammatory response to P. aeruginosa in CF bronchial cells.

OTHER RESULTS

FFC #3/2024

Two molecules are effective in activating Heat Shock Proteins and enhancing the action of CFTR correctors with the F508del mutation in vitro.

FFC#5/2024

Some peptide nucleic acids (PNAs) re-sensitise Pseudomonas aeruginosa to the antibiotic meropenem in vitro and reduce its virulence.

FFC#1/2023

Tezacaftor, one of the components of Kaftrio, induces an accumulation of dihydroceramides both in vitro and in vivo in animal models